---
title: "CTRI: Record Q2 2026 revenue and backlog, with strong growth and improved capital efficiency"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294822650.md"
description: "Q2 2026 saw record revenue and strong growth across all segments, with adjusted EPS up 26% and backlog reaching $6.4B. The JJ White acquisition expands union electric capabilities, while capital efficiency and leverage improved. Guidance for 2026 remains robust.Original document: Centuri Holdings, Inc. [CTRI] Slides Release — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T12:13:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294822650.md)
  - [en](https://longbridge.com/en/news/294822650.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294822650.md)
generator: "portal-rs"
---

# CTRI: Record Q2 2026 revenue and backlog, with strong growth and improved capital efficiency

Q2 2026 saw record revenue and strong growth across all segments, with adjusted EPS up 26% and backlog reaching $6.4B. The JJ White acquisition expands union electric capabilities, while capital efficiency and leverage improved. Guidance for 2026 remains robust.

Original document: Centuri Holdings, Inc. \[CTRI\] Slides Release — Aug. 4 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CTRI.US](https://longbridge.com/en/quote/CTRI.US.md)

## Related News & Research

- [Centuri wins more than $475 million in new customer awards](https://longbridge.com/en/news/296101813.md)
- [Did Centuri’s New Awards, Guidance Hike and Leadership Shuffle Just Shift Centuri Holdings' (CTRI) Investment Narrative?](https://longbridge.com/en/news/296250320.md)
- [One chart shows a big warning sign for the future of AI](https://longbridge.com/en/news/296329028.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**